Manaksia Coated Metals & Industries Fund Raise of ₹134.6 Cr

Manaksia Coated Metals & Industries Investor Presentation: Key Takeaways

Q2 FY27 total income Rs 321.55 Cr (+43.8% YoY), EBITDA Rs 36.91 Cr, PAT Rs 18.73 Cr (+34.2% YoY); EBITDA margin 11.48%. Capacity expansion and backward integration are underway.

Call

Guides 200% growth

Manaksia Coated Metals & Industries Capital Structure Change

Manaksia Coated Metals & Industries Ltd approved the opening of its QIP issue and set a floor price of ₹ 127.01 per share.

Manaksia Coated Metals & Industries Results Update

MCMIL reported record Q2 FY27 revenue of ₹321.55 Crore and PAT of ₹18.73 Crore. H1 FY27 revenue grew 22% YoY to ₹584.62 Crore.

Order book

₹525.0 Cr

Manaksia Coated Metals & Industries Convertible Warrants

Manaksia's monitoring report shows 20 lakh preferential warrants forfeited for unpaid balance, cutting the issue by Rs 9.75 crore. Objects are unfunded for the reduced amount.

Value

₹9.75 Cr

Manaksia Coated Metals & Industries Q2 FY27 Results: Net Profit ₹18.7 Cr, Up 33.6% YoY

Manaksia Coated Metals & Industries Ltd reported revenue from operations of ₹318.7 Cr (+44.7% YoY) and net profit of ₹18.7 Cr (+33.6% YoY) for Q2 FY27.

Key figure

Net profit ₹18.7 Cr · +33.6% YoY

Manaksia Coated Metals & Industries Board Meeting Date

Manaksia Coated Metals will hold a board meeting on October 28, 2026, to consider and approve its unaudited financial results for the quarter ending September 2026.

Sudarshan Pharma Industries Fund Raise of ₹72 Cr

Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.

Value

₹72.00 Cr

Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr

Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.

Value

₹68.20 Cr

Kanel Industries Fund Raise of ₹16.99 Cr

Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.

Value

₹16.99 Cr

Execution

Rights issue opens 23 November 2026 and closes 30 November 2026

Sudarshan Pharma Industries Fund Raise

Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.

GAIL (India) Fund Raise

GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.

Gujarat Inject (Kerala) Fund Raise of ₹3 Cr

Gujarat Inject Kerala's board approved a Rs.3 Crore preferential warrant issue to public investors. Authorised capital will rise to Rs.17.63 Crore, subject to shareholder approval.

Value

₹3.00 Cr